Explainable Artificial Intelligence in Neuroimaging of Alzheimer's Disease.

Abstract

Alzheimer's disease (AD) remains a significant global health challenge, affecting millions worldwide and imposing substantial burdens on healthcare systems. Advances in artificial intelligence (AI), particularly in deep learning and machine learning, have revolutionized neuroimaging-based AD diagnosis. However, the complexity and lack of interpretability of these models limit their clinical applicability. Explainable Artificial Intelligence (XAI) addresses this challenge by providing insights into model decision-making, enhancing transparency, and fostering trust in AI-driven diagnostics. This review explores the role of XAI in AD neuroimaging, highlighting key techniques such as SHAP, LIME, Grad-CAM, and Layer-wise Relevance Propagation (LRP). We examine their applications in identifying critical biomarkers, tracking disease progression, and distinguishing AD stages using various imaging modalities, including MRI and PET. Additionally, we discuss current challenges, including dataset limitations, regulatory concerns, and standardization issues, and propose future research directions to improve XAI's integration into clinical practice. By bridging the gap between AI and clinical interpretability, XAI holds the potential to refine AD diagnostics, personalize treatment strategies, and advance neuroimaging-based research.